COPD News

The Healio editors have compiled a list of the most-read pulmonology news published in September.

Older adults with COPD who were new users of oral cannabinoids had increased risk for all-cause mortality and those using higher doses had increased risk for hospitalization for COPD or pneumonia, according to data published in Thorax.

Nasal high-flow oxygen therapy may be an alternative to noninvasive ventilation in patients with chronic hypercapnic COPD, according to data presented at the virtual European Respiratory Society International Congress.

The FDA has approved Trelegy Ellipta, once-daily, single-inhaler triple therapy, for the new indication of treatment of asthma in adults, according to a company announcement.

The most prevalent comorbidity in patients hospitalized for COVID-19 was hypertension, which was also a risk factor for acute kidney injury in the ED and mortality in these patients, researchers found in two separate studies.

Adults who had childhood bronchitis were more likely to receive a diagnosis of pneumonia or asthma later in life, according to research presented at the virtual European Respiratory Society International Congress.

An additional course of ciprofloxacin 14 days after an unresolved COPD exacerbation did not benefit time to next event, compared with placebo, in patients with persistent symptoms and elevated C-reactive protein, according to recent data.

The Healio editors have compiled a list of the most-read pulmonology news published in August.

The FDA Pulmonary-Allergy Drugs Advisory Committee voted 14-1 against a proposed labeling claim that Trelegy Ellipta reduces all-cause mortality in patients with COPD.

A new clinical practice guideline addresses limited evidence and provides new recommendations for management of noninvasive ventilation in patients with COPD and chronic hypercapnia.